The Official Medicare Set Aside Blog And Information Resource

FDA Advisory Committee Finds Opana ER Risks Outweigh Benefits

FDA, Medicare Set-Aside Blog, Rx/Pharmacy on March 21, 2017
Posted by Erin O'Neill, PA-C, JD

On March 14, 2017, a Food and Drug Administration (FDA) advisory committee found that the risks associated with use of Opana ER (oxymorphone hydrochloride) outweighed the potential¬†benefits. Opana ER is an opioid pain medication, which was first introduced in 2006¬†and then reintroduced in a new abuse deterrent formulation in 2012. The new formulation was designed […] Continue